ABOVE: © ISTOCK.COM, KOTO_FEJA
Aclinical trial testing a novel gene therapy for a rare neurological disease has been put on hold after one of the participants in a Phase 3 trial developed a bone marrow disorder that can lead to cancer. The pause, announced Monday by the trial’s sponsor, bluebird bio, and mandated by the US Food and Drug Administration (FDA), was taken “out of an abundance of caution,” the company’s president of rare genetic diseases, Andrew Obenshain, said in a recent quarterly call.
The therapy targets cerebral adrenoleukodystrophy, which is caused by a mutation in the gene for an enzyme called adrenoleukodystrophy protein (ALDP) that breaks down fats. The mutation causes fat to build up in the brain, where it breaks down the insulating myelin that allows neurons to communicate with one another. Because the gene is on the X chromosome, women typically have a least one good copy, ...